Distribution
Amid “significant uncertainty” for the off-patent industry caused by the war in Iran, the IGBA has warned that a prolonged conflict “could make solvent supply a critical concern” while escalating costs and squeezed margins could affect the long-term sustainability of affordable medicines.
With concerns building over the potential impact on medicines supply of the war in Iran, Medicines for Europe and Medicines UK have offered a measured assessment of current supply-chain pressures and the potential for future disruption.
Nearly 50 medicines are now included in a Nordic pilot that relaxes language requirements on packaging to help improve access to essential hospital treatments.
In 2026, the Danish inspectors plan to focus on whether drug manufacturing procedures still match the approved marketing dossier, and will require wholesalers to show that the computerized systems used in distribution are fit for purpose.
Legal and other experts discuss the need to plug data privacy and regulatory gaps and address prescription shortcuts at e-pharmacies. Collaborative models with brick and mortar chemists were also proposed.
Legal and other experts discuss the need to plug data privacy and regulatory gaps and address prescription shortcuts at e-pharmacies. Collaborative models with brick-and-mortar chemists were also proposed.
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
Drug companies are being invited to participate in a new pilot project that the five Nordic countries will run to see if they can improve the availability of certain critical products that are used in hospitals.
Hyloris recognized that the suspension of its shares as part of a broader business fallout has “created uncertainty and temporarily impacted management and organizational focus,” as it got another commercial deal over the line for its Maxigesic IV (paracetamol/ibuprofen) solution for infusion.
ProBiotix Health has announced two commercial partnerships for the distribution of its probiotic ingredients, with Deutsch-Pharm in Ukraine and Eifron in Greece respectively.
Neuraxpharm is making further waves outside of Europe, launching operations in the Middle East just a year after entering Central and South America.
Regenerative Processing replaces nozzle to prevent backflow for its Regener-Eyes drops but FDA warning states numerous questions about sterility at the firm’s plant and about its procedures and systems for preventing microbial contamination.